Laminin subunit alpha 1 regulatory DNA (LAMA1 regulatory DNA)

Laminin subunit alpha 1 (LAMA1) regulatory DNA refers to the non-coding genomic sequences, including the promoter and enhancer regions, that control the transcription of the LAMA1 gene (UniProt P25391). While LAMA1 is primarily expressed during embryonic development and is largely absent in adult muscle, its regulatory DNA has become a significant therapeutic target for treating Congenital Muscular Dystrophy Type 1A (MDC1A). MDC1A is caused by mutations in the LAMA2 gene, leading to a deficiency in laminin-211 and subsequent muscle wasting; however, LAMA1 is a functional paralog that can compensate for this loss if its expression is reactivated (Kemaladewi et al., Nature 2019). Therapeutic strategies such as CRISPR activation (CRISPRa) utilize dCas9-based systems to target these regulatory elements, driving the endogenous production of laminin-111 to stabilize the basement membrane and improve muscle function (PubMed 31337615). This approach is particularly promising as a mutation-independent gene therapy that leverages the cell's own regulatory machinery to bypass genetic defects in related genes.

Other names

LAMA1 promoterLAMA1 enhancerLaminin alpha-1 regulatory sequenceLAMA1 upstream regulatory element

The mechanism involves the recruitment of synthetic transcriptional activators to the LAMA1 promoter or enhancer regions using a catalytically inactive Cas9 (dCas9) guided by specific RNAs. This targeted engagement induces the robust expression of the LAMA1 protein, which assembles into laminin-111 to functionally substitute for the deficient laminin-211 (LAMA2) in the extracellular matrix of muscle and nerve tissues (Kemaladewi et al., Nature 2019).